Free tool
FAERS Monitor: Revlimid
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021880 or its brand name (Revlimid, Lenalidomide). Reports on generic versions are filed under their own applications.
Reports
425,916
Serious
271,846
64% of reports
Hospitalization
110,525
Death reported
54,138
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea31,968
- fatigue27,107
- death26,885
- off label use19,177
- pneumonia19,040
- rash18,551
- plasma cell myeloma17,292
- neuropathy peripheral12,297
- white blood cell count decreased12,018
- constipation11,201
- nausea10,998
- asthenia10,240
- product dose omission issue10,080
- platelet count decreased9,655
- neutropenia9,518
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2005 | 15 |
| 2006 | 820 |
| 2007 | 1,497 |
| 2008 | 3,609 |
| 2009 | 2,897 |
| 2010 | 3,897 |
| 2011 | 6,340 |
| 2012 | 11,712 |
| 2013 | 10,519 |
| 2014 | 9,108 |
| 2015 | 34,550 |
| 2016 | 25,534 |
| 2017 | 28,602 |
| 2018 | 26,535 |
| 2019 | 30,129 |
| 2020 | 33,935 |
| 2021 | 52,556 |
| 2022 | 43,269 |
| 2023 | 29,356 |
| 2024 | 30,439 |
| 2025 | 23,903 |
| 2026 | 16,693 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,628,243 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| plasma cell myelomaSignal | 17,292 | 38.5 | 37.7 | 352,422 |
| neuropathy peripheralSignal | 12,297 | 7.2 | 7.0 | 57,240 |
| white blood cell count decreasedSignal | 12,018 | 6.0 | 5.9 | 45,094 |
| platelet count decreasedSignal | 9,655 | 4.8 | 4.7 | 26,708 |
| neutropeniaSignal | 9,518 | 3.6 | 3.6 | 17,071 |
| pneumoniaSignal | 19,040 | 3.0 | 3.0 | 24,639 |
| constipationSignal | 11,201 | 2.6 | 2.6 | 10,748 |
| diarrhoeaSignal | 31,968 | 2.5 | 2.5 | 28,763 |
| rashSignal | 18,551 | 2.2 | 2.1 | 11,164 |
| fatigue | 27,107 | 1.7 | 1.7 | 8,646 |
| product dose omission issue | 10,080 | 1.7 | 1.7 | 2,957 |
| death | 26,885 | 1.6 | 1.5 | 5,435 |
| asthenia | 10,240 | 1.4 | 1.3 | 941 |
| off label use | 19,177 | 1.1 | 1.1 | 125 |
| nausea | 10,998 | 0.7 | 0.7 | 1,673 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.